* Abeona Therapeutics announces data safety monitoring board
approves ABO-102 dose escalation for second cohort in phase 1/2
clinical trial for sanfilippo syndrome type A
The post BRIEF-Press release – Abeona Therapeutics announces approval of ABO-102 dose appeared first on NASDAQ.